Bringing the Patient Perspective into Rare Cancer Drug Review
Improving the lives of people affected by sarcoma requires scientific progress and public policies that support research, improve access to care, and ensure that patients help shape decisions affecting their treatment. SFA brings the sarcoma community’s needs into these policy conversations while supporting progress for people with rare diseases more broadly.
In October 2026, SFA engaged in two public meetings convened by FDA in partnership with the Reagan-Udall Foundation for the FDA. The October 16 meeting, “Patient Voice in Rare Disease Medical Product Development,” explored how patient perspectives are gathered during the development of drugs, biologics, and devices, how that input influences development, and opportunities to strengthen patient involvement.
The October 28 meeting focused on FDA’s Rare Disease Framework Initiative, which seeks to tailor drug development and regulatory review to the realities of rare diseases. FDA outlined its goals in the white paper “A New Framework for Rare Disease Review” and solicited public comments to help shape the framework. This initiative offers an important opportunity to address challenges facing sarcoma research, including small patient populations, differences among subtypes, and limited knowledge of how some diseases progress.
SFA’s comments called for meaningful patient and advocate involvement to become a required, documented part of drug development and regulatory review, with periodic opportunities for input at defined milestones from early planning through post-approval follow-up. We emphasized study outcomes that reflect what matters to patients, including survival, disease control, symptoms, function, and quality of life. We also called for continued patient involvement in assessing the relevance of those outcomes. Our recommendations also supported scientifically rigorous approaches appropriate for small populations, consultation with experts in individual sarcoma subtypes, and clear, consistent regulatory expectations. Together, these priorities aim to ensure that the distinct needs of rare and ultra-rare sarcoma communities inform how treatments are studied and evaluated. Brandi Felser, Nigel Brockton, and Kelley Argraves represented SFA at the October 28 meeting. SFA’s priorities will also be shared through written comments submitted to the public docket.
These efforts complement SFA’s broader public policy work, including advocacy for federal research funding, reducing barriers to clinical trial participation, and connecting patients and families with policymakers through Advocacy Weekend. Across these activities, our goal is to ensure that policies reflect the realities of living with sarcoma and support progress toward better treatments and care.